Corinna Jen-Hui Pan

Learn More
BACKGROUND Pegylated interferon (PEG-IFN)-α-2a improves the hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients. However, baseline factors predicting favourable responses to PEG-IFN-α-2a remain largely unknown. METHODS A total of 115 HBeAg-positive chronic hepatitis B patients who had a pre-therapy serum(More)
PURPOSE Acute exacerbation (AE) of chronic hepatitis B virus (HBV) infection is common and negatively impacts the clinical outcome. Factors predicting outcomes after exacerbations were only partly clarified. We investigated the host immune parameters associated with long-term outcomes. METHODS We prospectively examined the profiles of serum cytokines and(More)
  • 1